TAKEDA PHARMACEUTICAL CO LTD current report, Q4 FY2020

Abrir documento

Takeda Pharmaceutical Co Ltd: Form 6-K Summary

Business Context and Reporting Period

This Form 6-K filing, dated October 29, 2020, presents the Summary of Financial Statements for Takeda Pharmaceutical Company Limited for the six-month period ended September 30, 2020 (Fiscal Year 2020 H1). The results are prepared in accordance with International Financial Reporting Standards (IFRS). The company operates globally with major revenue contributions from the United States, Japan, and Europe/Canada.

Key Financial Metrics

Metric Period Ended Sep 30, 2020 Period Ended Sep 30, 2019 Change (%)
Revenue 1,590.8 Billion JPY 1,660.2 Billion JPY (4.2%)
Operating Profit 215.6 Billion JPY 109.0 Billion JPY 97.7%
Profit Before Tax 125.6 Billion JPY 31.2 Billion JPY 302.9%
Net Profit (Attributable to Owners) 86.5 Billion JPY 74.7 Billion JPY 15.8%
Basic EPS 55.45 JPY 48.01 JPY 15.5%
Core Operating Profit 507.6 Billion JPY 541.6 Billion JPY (6.3%)
Total Assets 12,414.7 Billion JPY 12,821.1 Billion JPY (Mar 31, 2020) N/A
Total Equity 4,666.5 Billion JPY 4,727.5 Billion JPY (Mar 31, 2020) N/A
Cash & Equivalents 630.9 Billion JPY 543.5 Billion JPY (Sep 30, 2019) N/A
Operating Cash Flow 392.0 Billion JPY 341.1 Billion JPY 14.9%

Material Changes vs. Prior Period

  • Revenue Decline: Reported revenue decreased 4.2% year-over-year. This was primarily driven by a 2.7 percentage point negative impact from the appreciation of the yen and a 20.6% decline in non-core therapeutic areas due to divestitures (e.g., ULORIC, COLCRYS) and generic erosion.
  • Operating Profit Surge: Operating profit nearly doubled (+97.7%) to 215.6 Billion JPY. This increase was significantly driven by a one-time gain of 60.2 Billion JPY from the release of the obligation to divest the pipeline compound SHP647. Excluding this and other non-recurring items, Core Operating Profit declined 6.3%.
  • Therapeutic Area Performance:
    • Gastroenterology (GI): Revenue increased 11.2%, driven by strong sales of ENTYVIO (+22.9%) and TAKECAB (+14.2%).
    • Rare Diseases: Revenue decreased 9.9%, impacted by declines in Rare Hematology (ADVATE, FEIBA) and Rare Metabolic (NATPARA recall impact).
    • PDT Immunology: Revenue increased 5.8%, fueled by strong demand for immunoglobulin products.
    • Neuroscience: Revenue decreased 2.8%, affected by generic competition (REMINYL) and temporary COVID-19 impacts on patient visits, though trends normalized by period end.
  • Cost Management: SG&A expenses decreased 9.5% due to cost synergies from the Shire integration and reduced spending on travel and events due to COVID-19.

Guidance, Outlook, and Risks

  • Revised Full-Year Forecast (FY2020):
    • Revenue: Lowered to 3,200 Billion JPY (from 3,250 Billion JPY) due to unfavorable foreign exchange assumptions.
    • Operating Profit: Raised to 434 Billion JPY (from 395 Billion JPY), reflecting expected one-time gains from announced divestitures.
    • Net Profit: Raised to 124 Billion JPY (from 92 Billion JPY).
    • Core Operating Profit: Unchanged at 984 Billion JPY.
  • Management Guidance: Remains unchanged with expectations for low-single-digit underlying revenue growth, high-single-digit underlying core operating profit growth, and low-teen underlying core EPS growth.
  • Dividends: Interim dividend of 90 JPY per share approved, payable December 1, 2020. Annual dividend policy remains 180 JPY per share.
  • COVID-19 Impact: Management states the pandemic did not have a material effect on H1 financial results. While Neuroscience saw temporary disruptions, trends normalized. The company anticipates no material liquidity issues but notes risks regarding supply chain, clinical trial delays, and potential future demand slowdowns.
  • Divestitures: Takeda announced an agreement to divest Takeda Consumer Healthcare Company Limited to Blackstone for an enterprise value of 242 Billion JPY. A pre-tax gain of approx. 140 Billion JPY is anticipated but not included in the current revised forecast pending closing.

Investor Verification Checklist

  • One-Time Gains: Verify the sustainability of the 97.7% operating profit increase, which is heavily influenced by the 60.2 Billion JPY non-recurring gain from the SHP647 divestiture release.
  • FX Sensitivity: Assess the impact of the strengthening yen on future revenue forecasts, which led to a 50 Billion JPY downward revision in full-year revenue guidance.
  • Core vs. Reported: Distinguish between reported metrics and "Underlying/Core" metrics; Core Operating Profit actually declined 6.3% year-over-year despite the reported surge.
  • Divestiture Timeline: Monitor the closing of the Takeda Consumer Healthcare sale to Blackstone to confirm the timing of the expected 140 Billion JPY gain recognition.
  • Product Pipeline: Review the status of the CoVIg-19 clinical trial and the Novavax vaccine partnership as potential future revenue drivers or risks.